Fibroblast growth factor-21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus and healthy subjects, and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions.